Cargando…

Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications

The appearance of tyrosine kinase inhibitors (TKIs) has been a major breakthrough in renal cell carcinoma (RCC) therapy. Unfortunately, a portion of patients with TKIs resistance experience disease progression after TKIs therapy. Epigenetic alterations play an important role in the development of TK...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qinhan, Zhang, Zhenan, Fan, Yu, Zhang, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835797/
https://www.ncbi.nlm.nih.gov/pubmed/33510766
http://dx.doi.org/10.3389/fgene.2020.562868
_version_ 1783642609937285120
author Li, Qinhan
Zhang, Zhenan
Fan, Yu
Zhang, Qian
author_facet Li, Qinhan
Zhang, Zhenan
Fan, Yu
Zhang, Qian
author_sort Li, Qinhan
collection PubMed
description The appearance of tyrosine kinase inhibitors (TKIs) has been a major breakthrough in renal cell carcinoma (RCC) therapy. Unfortunately, a portion of patients with TKIs resistance experience disease progression after TKIs therapy. Epigenetic alterations play an important role in the development of TKIs resistance. Current evidence suggests that epigenetic alterations occur frequently in RCC patients with poor response to TKIs therapy, and modulation of them could enhance the cytotoxic effect of antitumor therapy. In this review, we summarize the currently known epigenetic alterations relating to TKIs resistance in RCC, focusing on DNA methylation, non-coding RNAs (ncRNAs), histone modifications, and their interactions with TKIs treatment. In addition, we discuss application of epigenetic alteration analyses in the clinical setting to predict prognosis of patients with TKIs treatment, and the potential use of epigenetics-based therapies to surmount TKIs resistance.
format Online
Article
Text
id pubmed-7835797
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78357972021-01-27 Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications Li, Qinhan Zhang, Zhenan Fan, Yu Zhang, Qian Front Genet Genetics The appearance of tyrosine kinase inhibitors (TKIs) has been a major breakthrough in renal cell carcinoma (RCC) therapy. Unfortunately, a portion of patients with TKIs resistance experience disease progression after TKIs therapy. Epigenetic alterations play an important role in the development of TKIs resistance. Current evidence suggests that epigenetic alterations occur frequently in RCC patients with poor response to TKIs therapy, and modulation of them could enhance the cytotoxic effect of antitumor therapy. In this review, we summarize the currently known epigenetic alterations relating to TKIs resistance in RCC, focusing on DNA methylation, non-coding RNAs (ncRNAs), histone modifications, and their interactions with TKIs treatment. In addition, we discuss application of epigenetic alteration analyses in the clinical setting to predict prognosis of patients with TKIs treatment, and the potential use of epigenetics-based therapies to surmount TKIs resistance. Frontiers Media S.A. 2021-01-12 /pmc/articles/PMC7835797/ /pubmed/33510766 http://dx.doi.org/10.3389/fgene.2020.562868 Text en Copyright © 2021 Li, Zhang, Fan and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Li, Qinhan
Zhang, Zhenan
Fan, Yu
Zhang, Qian
Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
title Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
title_full Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
title_fullStr Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
title_full_unstemmed Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
title_short Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
title_sort epigenetic alterations in renal cell cancer with tkis resistance: from mechanisms to clinical applications
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835797/
https://www.ncbi.nlm.nih.gov/pubmed/33510766
http://dx.doi.org/10.3389/fgene.2020.562868
work_keys_str_mv AT liqinhan epigeneticalterationsinrenalcellcancerwithtkisresistancefrommechanismstoclinicalapplications
AT zhangzhenan epigeneticalterationsinrenalcellcancerwithtkisresistancefrommechanismstoclinicalapplications
AT fanyu epigeneticalterationsinrenalcellcancerwithtkisresistancefrommechanismstoclinicalapplications
AT zhangqian epigeneticalterationsinrenalcellcancerwithtkisresistancefrommechanismstoclinicalapplications